<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33576076</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1750-3639</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>May</Month></PubDate></JournalIssue><Title>Brain pathology (Zurich, Switzerland)</Title><ISOAbbreviation>Brain Pathol</ISOAbbreviation></Journal><ArticleTitle>Cognitive decline in amyotrophic lateral sclerosis: Neuropathological substrate and genetic determinants.</ArticleTitle><Pagination><StartPage>e12942</StartPage><MedlinePgn>e12942</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e12942</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1111/bpa.12942</ELocationID><Abstract><AbstractText>Cognitive impairment and behavioral changes in amyotrophic lateral sclerosis (ALS) are now recognized as part of the disease. Whether it is solely related to the extent of TDP-43 pathology is currently unclear. We aim to evaluate the influence of age, genetics, neuropathological features, and concomitant pathologies on cognitive impairment in ALS patients. We analyzed a postmortem series of 104 ALS patients and retrospectively reviewed clinical and neuropathological data. We assessed the burden and extent of concomitant pathologies, the role of APOE &#x3b5;4 and mutations, and correlated these findings with cognitive status. We performed a logistic regression model to identify which pathologies are related to cognitive impairment. Cognitive decline was recorded in 38.5% of the subjects. Neuropathological features of frontotemporal lobar degeneration (FTLD) were found in 32.7%, explaining most, but not all, cases with cognitive impairment. Extent of TDP-43 pathology and the presence of hippocampal sclerosis were associated with cognitive impairment. Mutation carriers presented a higher burden of TDP-43 pathology and FTLD more frequently than sporadic cases. Most cases (89.4%) presented some degree of concomitant pathologies. The presence of concomitant pathologies was associated with older age at death. FTLD, but also Alzheimer's disease, were the predominant underlying pathologies explaining the cognitive impairment in ALS patients. In sum, FTLD explained the presence of cognitive decline in most but not all ALS cases, while other non-FTLD related findings can influence the cognitive status, particularly in older age groups.</AbstractText><CopyrightInformation>&#xa9; 2021 The Authors. Brain Pathology published by John Wiley &amp; Sons Ltd on behalf of International Society of Neuropathology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Borrego-&#xc9;cija</LastName><ForeName>Sergi</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-2557-0010</Identifier><AffiliationInfo><Affiliation>Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Department, Hospital Cl&#xed;nic, Institut d'Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turon-Sans</LastName><ForeName>Janina</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neurology department, Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Networked Biomedical Research into Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ximelis</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Neurological Tissue Bank, Biobanc-Hospital Cl&#xed;nic-IDIBAPS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aldecoa</LastName><ForeName>Iban</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Neurological Tissue Bank, Biobanc-Hospital Cl&#xed;nic-IDIBAPS, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pathology Department, CDB, Hospital Clinic Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molina-Porcel</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Department, Hospital Cl&#xed;nic, Institut d'Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurological Tissue Bank, Biobanc-Hospital Cl&#xed;nic-IDIBAPS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Povedano</LastName><ForeName>M&#xf3;nica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Service of Neurology, Motor Neuron Unit, IDIBELL, Bellvitge University Hospital, Hospitalet de Llobregat, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rubio</LastName><ForeName>Miguel Angel</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Neuromuscular Unit, Department of Neurology, Hospital del Mar, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xe1;mez</LastName><ForeName>Josep</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>ALS Unit, Neurology Department, Vall d'Hebr&#xf3;n University Hospital, Vall d'Hebr&#xf3;n Research Institute (VHIR).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>European Reference Network on Rare Neuromuscular Diseases (ERN EURO-NMD), Department of Medicine, UAB, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cano</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurology Department, Hospital de Matar&#xf3;, Matar&#xf3;, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Par&#xe9;-Curell</LastName><ForeName>Mart&#xed;</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0627-5350</Identifier><AffiliationInfo><Affiliation>Neurology Department, Hospital Germans Trias i Pujol, Badalona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bajo</LastName><ForeName>Lorena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Servei de Geriatria, Fundaci&#xf3; Hospital de la Santa Creu, Hospital Universitari de la Santa Creu de Vic, Vic, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sotoca</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neurology Department, Hospital Mutua de Terrassa, Terrassa, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clarim&#xf3;n</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neurology department, Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Networked Biomedical Research into Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balasa</LastName><ForeName>Mircea</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Department, Hospital Cl&#xed;nic, Institut d'Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antonell</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Department, Hospital Cl&#xed;nic, Institut d'Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Llad&#xf3;</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Department, Hospital Cl&#xed;nic, Institut d'Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez-Valle</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Department, Hospital Cl&#xed;nic, Institut d'Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurological Tissue Bank, Biobanc-Hospital Cl&#xed;nic-IDIBAPS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rojas-Garc&#xed;a</LastName><ForeName>Ricard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Neurology department, Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Networked Biomedical Research into Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gelpi</LastName><ForeName>Ellen</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-2948-4187</Identifier><AffiliationInfo><Affiliation>Neurological Tissue Bank, Biobanc-Hospital Cl&#xed;nic-IDIBAPS, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Brain Pathol</MedlineTA><NlmUniqueID>9216781</NlmUniqueID><ISSNLinking>1015-6305</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="N">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009422" MajorTopicYN="N">Nervous System Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069338" MajorTopicYN="N">Neuropathology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS-FTD</Keyword><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">TDP-43 protein</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">neuropathology</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33576076</ArticleId><ArticleId IdType="pmc">PMC8412113</ArticleId><ArticleId IdType="doi">10.1111/bpa.12942</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goldstein LH, Abrahams S. Changes in cognition and behaviour in amyotrophic lateral sclerosis: nature of impairment and implications for assessment. Lancet Neurol. 2013;12:368&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">23518330</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH, Woolley S, Mclaughlin P, Snowden J, et al. Amyotrophic lateral sclerosis &#x2010; frontotemporal spectrum disorder (ALS&#x2010;FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Front Degener. 2017;18:153&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7409990</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudlo J, K&#xf6;nig J, Schuster C, Kasper E, B&#xfc;ttner A, Teipel S, et al. TDP&#x2010;43 pathology and cognition in ALS. Neurology. 2016;87:1019&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">27488596</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxon JA, Harris JM, Thompson JC, Jones M, Richardson AMT, Langheinrich T, et al. Semantic dementia, progressive non&#x2010;fluent aphasia and their association with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2017;88:711&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5537533</ArticleId><ArticleId IdType="pubmed">28554960</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Grace GM, Freedman M, Lomen&#x2010;Hoerth C, Woolley S, Goldstein LH, et al. Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009;10:131&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">19462523</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrell JR, Halliday GM, Kril JJ, Ittner LM, G&#xf6;tz J, Kiernan MC, et al. The frontotemporal dementia&#x2010;motor neuron disease continuum. Lancet. 2016;388:919&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">26987909</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Alafuzoff I, Al&#x2010;Sarraj S, Arzberger T, Bogdanovic N, Capellari S, et al. Mixed brain pathologies in dementia: The BrainNet Europe consortium experience. Dement Geriatr Cogn Disord. 2008;26:343&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">18849605</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahimi J, Kovacs GG. Prevalence of mixed pathologies in the aging brain. Alzheimer&#x2019;s Res Ther. 2014;6:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4239398</ArticleId><ArticleId IdType="pubmed">25419243</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL, Lee EB, Xie SX, Rennert L, Suh E, Bredenberg C, et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age&#x2010;related and APOE4&#x2010;associated. Brain. 2018;141:2181&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6022546</ArticleId><ArticleId IdType="pubmed">29878075</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser PS, Ryan RO. Impact of apolipoprotein E on Alzheimer&#x2019;s disease. Curr Alzheimer Res. 2013;10:809&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3995977</ArticleId><ArticleId IdType="pubmed">23919769</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J, Tan L, Hardy J. Apolipoprotein E in Alzheimer&#x2019;s disease: an update. Annu Rev Neurosci. 2014;37:79&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">24821312</ArticleId></ArticleIdList></Reference><Reference><Citation>Wennberg AM, Tosakulwong N, Lesnick TG, Murray ME, Whitwell JL, Liesinger AM, et al. Association of apolipoprotein E &#x3f5;4 with transactive response DNA&#x2010;binding protein 43. JAMA Neurol. 2018;75:1347&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6248121</ArticleId><ArticleId IdType="pubmed">30422173</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang HS, Yu L, White CC, Chibnik LB, Chhatwal JP, Sperling RA, et al. Evaluation of TDP&#x2010;43 proteinopathy and hippocampal sclerosis in relation to APOE &#x3b5;4 haplotype status: a community&#x2010;based cohort study. Lancet Neurol. 2018;17:773&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6154505</ArticleId><ArticleId IdType="pubmed">30093249</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Brunetti M, Barberis M, Iazzolino B, Montuschi A, Ilardi A, et al. The role of APOE in the occurrence of frontotemporal dementia in amyotrophic lateral sclerosis. JAMA Neurol. 2016;73:425&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">26903389</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubino E, Vacca A, Govone F, De Martino P, Pinessi L, Rainero I. Apolipoprotein E polymorphisms in frontotemporal lobar degeneration: A meta&#x2010;analysis. Alzheimer&#x2019;s Dement. 2013;9:706&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">23688578</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyagawa T, Brushaber D, Syrjanen J, Kremers W, Fields J, Forsberg LK, et al. Utility of the global CDR&#xae; plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium. Alzheimers Dement. 2020;16:106&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7202045</ArticleId><ArticleId IdType="pubmed">31914218</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno&#x2010;Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059138</ArticleId><ArticleId IdType="pubmed">21325651</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(9):2456&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB, Robinson JL, Irwin DJ, Grossman M, et al. Stages of pTDP&#x2010;43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74:20&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Bigio EH, Mackenzie IRA, Schneider JA, Paulo UDS, Paulo S, et al. Neuropathological diagnostic and nosologic criteria for FTLD : consensus of the Consortium for FLTD. Acta Neuropathol. 2010;114:5&#x2013;22.</Citation></Reference><Reference><Citation>Mackenzie IR, Neumann M. Reappraisal of TDP&#x2010;43 pathology in FTLD&#x2010;U subtypes. Acta Neuropathol. 2017;134:79&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">28466142</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauramaa T, Pikkarainen M, Englund E, Ince PG, Jellinger K, Paetau A, et al. Consensus recommendations on pathologic changes in the hippocampus: a postmortem multicenter inter&#x2010;rater study. J Neuropathol Exp Neurol. 2013;72:452&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">23656988</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan RH, Kril JJ, Fatima M, McGeachie A, McCann H, Shepherd C, et al. TDP&#x2010;43 proteinopathies: Pathological identification of brain regions differentiating clinical phenotypes. Brain. 2015;138:3110&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">26231953</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease&#x2010;associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112:389&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, R&#xfc;b U, Orantes M, Braak H. Phases of A beta&#x2010;deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41(4):479.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National institute on aging&#x2010;Alzheimer&#x2019;s association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: a practical approach. Acta Neuropathol. 2012;123:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I, et al. Primary age&#x2010;related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014;128:755&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4257842</ArticleId><ArticleId IdType="pubmed">25348064</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Ferrer I, Grinberg LT, Alafuzoff I, Attems J, Budka H, et al. Aging&#x2010;related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathol. 2016;131:87&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4879001</ArticleId><ArticleId IdType="pubmed">26659578</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies. Neurology. 2017;89(1):88&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5496518</ArticleId><ArticleId IdType="pubmed">28592453</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito Y, Ruberu NN, Sawabe M, Arai T, Tanaka N, Kakuta Y, et al. Staging of argyrophilic grains: an age&#x2010;associated tauopathy. J Neuropathol Exp Neurol. 2004;63:911&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15453090</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, et al. Limbic&#x2010;predominant age&#x2010;related TDP&#x2010;43 encephalopathy (LATE): consensus working group report. Brain. 2019;142:1503&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6536849</ArticleId><ArticleId IdType="pubmed">31039256</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Del Tredici K, Ludolph AC, Hoozemans JJM, Rozemuller AJ, Braak H, et al. Stages of granulovacuolar degeneration: their relation to Alzheimer&#x2019;s disease and chronic stress response. Acta Neuropathol. 2011;122:577&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">21935637</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos&#x2010;campoy O, Avila&#x2010;polo R, Rojas&#x2010;garc R, Charif S, Santiago&#x2010;valera V, Hernandez I, et al. Systematic screening of Ubiquitin/p62 aggregates in cerebellar cortex expands the neuropathological phenotype of the C9orf72 expansion mutation. J Neuropathol Exp Neurol. 2018;77:703&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">29889265</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Sim&#xf3;n&#x2010;S&#xe1;nchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21&#x2010;linked ALS&#x2010;FTD. Neuron. 2011;72:257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Dols&#x2010;Icardo O, Garc&#xed;a&#x2010;Redondo A, Rojas&#x2010;Garc&#xed;a R, Borrego&#x2010;Hern&#xe1;ndez D, Ill&#xe1;n&#x2010;Gala I, Mu&#xf1;oz&#x2010;Blanco JL, et al. Analysis of known amyotrophic lateral sclerosis and frontotemporal dementia genes reveals a substantial genetic burden in patients manifesting both diseases not carrying the C9orf72 expansion mutation. J Neurol Neurosurg Psychiatry. 2018;89:162&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28889094</ArticleId></ArticleIdList></Reference><Reference><Citation>Cort&#xe9;s&#x2010;Vicente E, Turon&#x2010;Sans J, Gelpi E, Clarim&#xf3;n J, Borrego&#x2010;&#xc9;cija S, Dols&#x2010;Icardo O, et al. Distinct clinical features and outcomes in motor neuron disease associated with behavioural variant frontotemporal dementia. Dement Geriatr Cogn Disord. 2018;45:220&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">29886477</ArticleId></ArticleIdList></Reference><Reference><Citation>Coan G, Mitchell CS. An assessment of possible neuropathology and clinical relationships in 46 sporadic amyotrophic lateral sclerosis patient autopsies. Neurodegener Dis. 2015;15:301&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4560965</ArticleId><ArticleId IdType="pubmed">26183171</ArticleId></ArticleIdList></Reference><Reference><Citation>Borrego&#x2010;&#xc9;cija S, Cort&#xe9;s&#x2010;Vicente E, Cervera&#x2010;Carles L, Clarim&#xf3;n J, G&#xe1;mez J, Batlle J, et al. Does ALS&#x2010;FUS without FUS mutation represent ALS&#x2010;FET? Report of three cases. Neuropathol Appl Neurobiol. 2019;45:421&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7380051</ArticleId><ArticleId IdType="pubmed">30375034</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer KR, Foster ZW, Rauf NA, Guilderson L, Collins D, Averill JG, et al. Neuropathological profile of long&#x2010;duration amyotrophic lateral sclerosis in military veterans. Brain Pathol. 2020. 10.1111/bpa.12876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12876</ArticleId><ArticleId IdType="pmc">PMC8018169</ArticleId><ArticleId IdType="pubmed">32633852</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrell JR, Kiernan MC, Vucic S, Hodges JR. Motor neuron dysfunction in frontotemporal dementia. Brain. 2011;134:2582&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">21840887</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold SJ, Dugger BN, Beach TG. TDP&#x2010;43 deposition in prospectively followed, cognitively normal elderly individuals: Correlation with argyrophilic grains but not other concomitant pathologies. Acta Neuropathol. 2013;126:51&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3691299</ArticleId><ArticleId IdType="pubmed">23604587</ArticleId></ArticleIdList></Reference><Reference><Citation>Soma K, Fu Y&#x2010;J, Wakabayashi K, Onodera O, Kakita A, Takahashi H. Co&#x2010;occurrence of argyrophilic grain disease in sporadic amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol. 2012;38:54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">21702760</ArticleId></ArticleIdList></Reference><Reference><Citation>Riku Y, Duyckaerts C, Boluda S, Plu I, Le Ber I, Millecamps S, et al. Increased prevalence of granulovacuolar degeneration in C9orf72 mutation. Acta Neuropathol. 2019;138:783&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">31144027</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Schoor E, Koper MJ, Ospitalieri S, Dedeene L, Tom&#xe9; SO, Vandenberghe R, et al. Necrosome&#x2010;positive granulovacuolar degeneration is associated with TDP&#x2010;43 pathological lesions in the hippocampus of ALS/FTLD cases. Neuropathol Appl Neurobiol. 2020. https://pubmed.ncbi.nlm.nih.gov/32949047/. Accessed 9 Dec 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">32949047</ArticleId></ArticleIdList></Reference><Reference><Citation>Su WH, Shi ZH, Liu SL, Wang XD, Liu S, Ji Y. Updated meta&#x2010;analysis of the role of APOE &#x3b5;2/&#x3b5;3/&#x3b5;4 alleles in frontotemporal lobar degeneration. Oncotarget. 2017;8:43721&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5546436</ArticleId><ArticleId IdType="pubmed">28487499</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda T, Seilhean D, Le Ber I, Millecamps S, Sazdovitch V, Kitagawa K, et al. Amygdala TDP&#x2010;43 pathology in frontotemporal lobar degeneration and motor neuron disease. J Neuropathol Exp Neurol. 2017;76:800&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">28859337</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>